Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Laboratoire de virologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France.
Int J Infect Dis. 2022 Dec;125:135-137. doi: 10.1016/j.ijid.2022.10.031. Epub 2022 Oct 29.
A patient aged 28 years who is immunocompromised and living with HIV/AIDS became infected with the monkeypox virus (MPXV). His clinical condition deteriorated for 37 days, with fever, skin lesions, and diarrhea before going to the infectious diseases department, where his severe, protracted infection was treated with tecovirimat for 14 days. His condition rapidly improved, and the skin lesions decreased, as did the MPXV loads, with no adverse events. This case indicates that tecovirimat might be effective for treating patients who are immunocompromised and are infected with MPXV.
一名 28 岁的免疫功能低下的艾滋病毒/艾滋病患者感染了猴痘病毒（MPXV）。他在前往传染病科之前，已经发烧、皮肤损伤和腹泻了 37 天，在那里他的严重、迁延性感染用特考韦瑞玛治疗了 14 天。他的病情迅速改善，皮肤损伤减少，MPXV 载量也减少，没有出现不良反应。本病例表明，特考韦瑞玛可能对治疗免疫功能低下且感染 MPXV 的患者有效。
